Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin treatment in Philadelphia-negative chronic myeloproliferative neoplasms
2024-518267-35-00Phase 2Authorised
- Sponsor
- Region Zealand
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atorvastatin in myeloproliferative disorder (MPD), thrombocythemia, polycythemia vera (PV) and 1 more, sponsored by Region Zealand. Primary endpoints: Inflammatory parameters, hs-CRP and 4 more. Planned start Jun 2025; status: authorised.
02
Drugs
atorvastatin
03
Conditions
myeloproliferative disorder (MPD)thrombocythemiapolycythemia vera (PV)primary myelofibrosis (PMF)
Beyond the preview
Go deeper on 2024-518267-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518267-35-00.